Zogenix Inc. (NASDAQ: ZGNX) has submitted its supplemental new drug application (sNDA) with the U.S. Food and Drug Administration, we have seen some analyst commentary that is worth noting. Oppenheimer’s Akiva Felt and Angad Verma have issued their report. The official rating remains as Outperform, but what stands out here is that the $2.50 price target implies that Zogenix can more than double from the … Continue reading Stocks to Watch : Zogenix, Inc. (NASDAQ:ZGNX), Morgan Stanley (NYSE:MS), China Biologic Products, Inc. (NASDAQ:CBPO), Resonant Inc. (NASDAQ:RESN), Arbor Realty Trust Inc. (NYSE:ABR)